Close Menu

National Geographic

NatGeo will continue to conduct research using its database, which includes data on roughly a million individuals.

Consumer genomics companies have endeavored to reach out to minority communities with sometimes contentious results.

With ever more data in hand, providers are seeking to enhance their services, providing more detailed ancestry estimates while introducing new offerings around genetic traits and health.

With the rollout of Insitome's first app, consumers have the chance to explore their heritage in a new context that could reshape the ancestry testing market.

The company has developed a suite of initial products focused on ancestry that will compete with offerings from 23andMe, AncestryDNA, and Family Tree DNA.

Living DNA can break down the origins of a customer’s ancestry into 21 distinct regions within Britain alone, as well as across 80 different worldwide populations.

Bella

Embark hopes the test will not only satisfy the curiosity of pet owners but advance both canine and human health research.

Thanks to a new array, NatGeo will now offer customers expanded Y chromosome and mtDNA analyses, setting it apart in a competitive consumer genomics market.

The value of consumer genomics services is increasing as customers seek to discover new cousins and adoptees track down their biological birth parents.

The term 'consumer genomics' may have a catch-all ring to it, but for the time being it means ancestry testing and genetic genealogy, including for companies such as 23andMe, which built its business on relaying both personal health information and ancestral information back to c

Pages

NPR says the explosion and fire earlier this week at a Russian lab that stores dangerous pathogens revives the question of whether such samples should be kept.

According to Wired, Nebula Genomics is providing a way for people to get their genomes sequenced anonymously.

A 26-year-old woman tells Cosmopolitan about learning her APOE status at a young age.

In Science journals this week: a functional genomic screen uncovers drug combination that increases KRAS inhibitor efficacy in aggressive lung cancer, and more.